Intra-Cellular Therapies, Inc.
ITCI
$131.87
-$0.05-0.04%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 199.22M | 175.38M | 161.39M | 144.87M | 132.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 199.22M | 175.38M | 161.39M | 144.87M | 132.10M |
| Cost of Revenue | 90.69M | 82.12M | 67.54M | 52.73M | 61.48M |
| Gross Profit | 108.53M | 93.25M | 93.85M | 92.13M | 70.62M |
| SG&A Expenses | 137.73M | 132.10M | 121.57M | 113.09M | 104.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.42M | 214.22M | 189.11M | 165.82M | 166.20M |
| Operating Income | -29.20M | -38.85M | -27.72M | -20.95M | -34.10M |
| Income Before Tax | -17.20M | -25.95M | -16.16M | -14.89M | -28.13M |
| Income Tax Expenses | -317.00K | 374.00K | 57.00K | 359.00K | 448.00K |
| Earnings from Continuing Operations | -16.89M | -26.32M | -16.22M | -15.25M | -28.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.89M | -26.32M | -16.22M | -15.25M | -28.58M |
| EBIT | -29.20M | -38.85M | -27.72M | -20.95M | -34.10M |
| EBITDA | -29.09M | -38.71M | -27.59M | -20.82M | -33.96M |
| EPS Basic | -0.16 | -0.25 | -0.16 | -0.16 | -0.30 |
| Normalized Basic EPS | -0.10 | -0.15 | -0.10 | -0.10 | -0.18 |
| EPS Diluted | -0.16 | -0.25 | -0.16 | -0.16 | -0.30 |
| Normalized Diluted EPS | -0.10 | -0.15 | -0.10 | -0.10 | -0.18 |
| Average Basic Shares Outstanding | 106.10M | 105.77M | 103.72M | 96.88M | 96.29M |
| Average Diluted Shares Outstanding | 106.10M | 105.77M | 103.72M | 96.88M | 96.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
